ZOLGENSMA INCAL Trademark
Trademark Overview
On Monday, January 29, 2024, a trademark application was filed for ZOLGENSMA INCAL with the United States Patent and Trademark Office. The USPTO has given the ZOLGENSMA INCAL trademark a serial number of 79392220. The federal status of this trademark filing is PRIORITY ACTION MAILED as of Thursday, January 2, 2025. This trademark is owned by Novartis AG. The ZOLGENSMA INCAL trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparations in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
General Information
| Serial Number | 79392220 |
| Word Mark | ZOLGENSMA INCAL |
| Filing Date | Monday, January 29, 2024 |
| Status | 658 - PRIORITY ACTION MAILED |
| Status Date | Thursday, January 2, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparations in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 29, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Novartis AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | CH |
Trademark Events
| Event Date | Event Description |
| Monday, April 8, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, April 8, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, April 8, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, March 28, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, March 29, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, April 2, 2024 | APPLICATION FILING RECEIPT MAILED |
| Monday, April 8, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, April 8, 2024 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Monday, April 8, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, December 16, 2024 | PRIORITY ACTION WRITTEN |
| Tuesday, December 17, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, January 2, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, January 17, 2025 | REFUSAL PROCESSED BY IB |
| Thursday, January 2, 2025 | REFUSAL PROCESSED BY MPU |
| Friday, August 9, 2024 | ASSIGNED TO EXAMINER |
| Monday, December 16, 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Monday, December 16, 2024 | PRIORITY ACTION E-MAILED |
